Jun 23, 2025, 07:07
TOP Biotechs at ASCO: David Spetzler on AI Signatures in NSCLC, Pancreatic Cancer, Recurrence
In this episode of TOP Biotechs at ASCO, filmed at the ASCO 2025 Annual Meeting, David Spetzler, President of Caris Life Sciences, highlights the latest advancements in applying artificial intelligence (AI) to molecular oncology.
Highlights:
- AI-driven signatures are now predicting cancer recurrence up to 15 years based on a simple H&E image.
- Identification of non-small cell lung cancer (NSCLC) patients with PD-L1 positivity who still derive benefit from adding chemotherapy.
- AI is helping stratify pancreatic cancer subpopulations that show comparable outcomes on different treatment regimens.
- The progress of next-generation sequencing (NGS) over the past two decades continues to reshape cancer research and clinical decision-making.
David Spetzler shares how the integration of AI and molecular data is driving a new era of personalized cancer care—an exciting theme emerging across this year’s ASCO 2025 presentations.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 07:59
Jun 23, 2025, 07:42
Jun 23, 2025, 07:30